99. 慢性特発性偽性腸閉塞症 Chronic intestinal pseudo-obstruction Clinical trials / Disease details
臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-000854-24-IT (EUCTR) | 17/09/2021 | 18/10/2021 | Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO) | Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A | Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary. MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Velusetrag Product Code: [TD-5108 hydrochloride] INN or Proposed INN: Velusetrag Other descriptive name: THRX-199687 hydrochloride | ALFASIGMA S.P.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 2 | Spain;Belgium;Italy | ||
| 2 | NCT04118699 (ClinicalTrials.gov) | December 25, 2019 | 23/9/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial | Chronic Intestinal Pseudo-obstruction | Drug: Rifaximin oral tablet;Drug: Placebo oral tablet | Yokohama City University | ASKA Pharmaceutical Co., Ltd. | Active, not recruiting | 20 Years | 74 Years | All | 12 | Phase 2 | Japan |
| 3 | JPRN-jRCT2031190137 | 25/12/2019 | 20/11/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Chronic Intestinal Pseudo-obstruction CIPO, abdominal bloating | Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks. | Ohkubo Hidenori | NULL | Not Recruiting | >= 20age old | < 75age old | Both | 12 | Phase 2 | Japan |
| 4 | NCT00793247 (ClinicalTrials.gov) | December 2008 | 18/11/2008 | Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP) | A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP). | Chronic Intestinal Pseudo-Obstruction | Drug: PRU-PLA-PRU-PLA;Drug: PLA-PRU-PLA-PRU;Drug: PLA-PRU-PRU-PLA;Drug: PRU-PLA-PLA-PRU | Movetis | NULL | Completed | 18 Years | N/A | Both | Phase 2 | United Kingdom |